The Efficacy and Evidence-Based Use of Biologics in Children and Adolescents.
CONCLUSION: The retrieved trials have deficiencies that make it difficult to reliably evaluate the efficacy, safety, and utility of mAb/FP for children and adolescents with chronic inflammatory diseases. mAb/FP nonetheless represent a treatment option to be considered in case conventional immune-modulating drugs are ineffective. Researcher-initiated, high-quality trials and manufacturer-independent, systematic long-term evaluations of adverse effects (e.g., tumors) are sorely needed.
PMID: 31711560 [PubMed - in process]
Source: Deutsches Arzteblatt International - Category: General Medicine Tags: Dtsch Arztebl Int Source Type: research
More News: Abatacept | Actemra | Arthritis | Asthma | Bronchial Tumour | Children | Databases & Libraries | Enbrel | General Medicine | Humira | Inflammatory Bowel Disease | Orencia | Pediatrics | Psoriasis | Remicade | Rheumatology | Stelara | Xolair